Hypothesis / aims of study Endothelin-1 (ET-1) was shown to induce prolonged contractile responses in isolated bladder muscle strips in various species [1]. ET-1 binding sites were identified in detrusor smooth muscles, epithelia, and vascular endothelium [2]. ET-1 is synthesized not only by smooth muscle cells in the urinary bladder, but also by epithelial cells and fibroblasts. Furthermore, the intravenous infusion of ET-1 was shown to cause a decrease in the mean micturition volume of rats in addition to an increase in mean arterial pressure [3]. Selective ETA receptor antagonists have ameliorating effects on various urinary dysfunctions including benign prostatic hyperplasia. The protective effect of an endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction has also been demonstrated. These studies clearly indicate the existence of functional receptors for endothelins in the bladder, which could be a promising target for the treatment of lower urinary tract symptoms. Bladder endothelin receptors have been briefly identified. However, bladder ET-1 receptor binding of endothelin receptor antagonists used for the treatment of pulmonary arterial hypertension has not been examined in detail. Based on these pharmacological results, the present study aimed to directly identify ET-1 receptors in the rat bladder by a radioligand binding assay and characterize bladder receptor binding of the clinically used ET-1 receptor antagonists, bosentan and ambrisentan.
BLADDER ENDOTHELIN-1 RECEPTOR BINDING OF BOSENTAN AND AMBRISENTAN
Hypothesis / aims of study Endothelin-1 (ET-1) was shown to induce prolonged contractile responses in isolated bladder muscle strips in various species [1] . ET-like immunoreactivity and [ 125 ]ET-1 binding sites were identified in detrusor smooth muscles, epithelia, and vascular endothelium [2] . ET-1 is synthesized not only by smooth muscle cells in the urinary bladder, but also by epithelial cells and fibroblasts. Furthermore, the intravenous infusion of ET-1 was shown to cause a decrease in the mean micturition volume of rats in addition to an increase in mean arterial pressure [3] . Selective ETA receptor antagonists have ameliorating effects on various urinary dysfunctions including benign prostatic hyperplasia. The protective effect of an endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction has also been demonstrated. These studies clearly indicate the existence of functional receptors for endothelins in the bladder, which could be a promising target for the treatment of lower urinary tract symptoms. Bladder endothelin receptors have been briefly identified. However, bladder ET-1 receptor binding of endothelin receptor antagonists used for the treatment of pulmonary arterial hypertension has not been examined in detail. Based on these pharmacological results, the present study aimed to directly identify ET-1 receptors in the rat bladder by a radioligand binding assay and characterize bladder receptor binding of the clinically used ET-1 receptor antagonists, bosentan and ambrisentan. (Table 2 ). The significant decrease at the 100 mg/kg bosentan was seen at 1 and 3 h after the oral administration.
Interpretation of results [ 125 I]ET-1 labels selectively bladder ET-1 receptors in rats. Selective antagonists of ET-1 receptors at pharmacological doses may bind to these ET-1 receptors, thereby suggesting some effects on the physiological functions of bladder. Also, bosentan and ambrisentan was shown to bind bladder ET-1 receptor in competitive and reversible manner. Oral administration of bosentan caused a dose-dependent decrease in Bmax for bladder [
125 I]ET-1 binding, suggesting significant binding of bladder ET-1 receptors in vivo. A significant amount of pharmacologically relevant ET-1 receptors may exist in the bladder. These receptors may be implicated in the pathogenesis of lower urinary tract symptoms and may also be promising targets for the development of therapeutic agents.
Concluding message
The major findings of this study are that 1) a significant amount of high affinity receptors for ET-1 exists in the rat bladder and 2) bosenan and ambrisentan may bind to these ET-1 receptors, which suggests some effects on the physiological functions of the bladder. 
